Population modeling in patients with sunitinib-treated cancer

The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Continue reading

H.E. the United States Ambassador in Greece visits UPAT and gets informed about the U-PGx project

On July 21st, 2017, H.E. the United States Ambassador to Greece Mr. Geoffrey Pyatt visited the Laboratory of Molecular Biology and Immunology, University of Patras (UPAT), as part of his visit to academic entities in Patras that produce and offer innovative results and services in the biotechnology and healthcare sectors.

Continue reading

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programmes have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps.  Continue reading